First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data expected by year-end
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
Seeking Alpha / 2 hours from now 1 Views
Comments